Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
about
Dynamic electrophoretic fingerprinting of the HIV-1 envelope glycoprotein.Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodiesIdentification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunizationDissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens.Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responsesIncreased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration.Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma virusesDevelopment and characterization of an equine infectious anemia virus Env-pseudotyped reporter virusA monoclonal antibody against lymphocyte function-associated antigen-1 decreases HIV-1 replication by inducing the secretion of an antiviral soluble factor.Detection of HIV gp120 in plasma during early HIV infection is associated with increased proinflammatory and immunoregulatory cytokines
P2860
Q30454762-A83B06C6-B6D9-4378-BE74-20341D1B275CQ33274285-7E39604E-117C-4E17-986A-42972F07C505Q34428738-513A44B4-9653-4F2F-B07C-998574D5BA6CQ34637968-73C7193A-1517-45ED-A938-9F521E04BDA5Q35208657-264FDB19-6911-4FFA-BCD1-C43185C315D0Q35828002-479C8466-9ABF-43E8-92F5-E114EA163D9AQ35857221-5107E3CA-56BB-4E7F-B5F8-08BB8A89FDE1Q35933555-A478E5F2-AEBD-4476-95DE-3AA0E8770961Q36141515-2C047A6B-B6BE-45FE-BF9A-695B338A2A48Q36424574-88EA783D-DB63-4D8B-B718-1B1493A3773EQ36496923-23067EDE-1EFB-468D-8248-0C18D53C5D24Q36502557-0D5C2369-5D0C-4880-B53F-EA8A321980E7Q36746968-369FE816-6426-4C81-A3F9-221D5F95F25AQ36827975-A9201F75-DF3D-4CB6-BFFA-A36CD93CEC06Q42115835-F9CF4E21-4064-442C-B27F-56764234F304
P2860
Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Neutralization and infectivity ...... eactive neutralizing activity.
@en
Neutralization and infectivity ...... eactive neutralizing activity.
@nl
type
label
Neutralization and infectivity ...... eactive neutralizing activity.
@en
Neutralization and infectivity ...... eactive neutralizing activity.
@nl
prefLabel
Neutralization and infectivity ...... eactive neutralizing activity.
@en
Neutralization and infectivity ...... eactive neutralizing activity.
@nl
P2093
P1433
P1476
Neutralization and infectivity ...... eactive neutralizing activity.
@en
P2093
Fatim Cham
Gerald V Quinnan
Guido van der Groen
Herman Katinger
James Robinson
Leo Heyndrickx
Peng Fei Zhang
Peter Bouma
Ping Zhong
P356
10.1016/J.VIROL.2005.11.019
P407
P577
2005-12-27T00:00:00Z